Glibenclamide + Metformin Tablet Franchise in Ahmedabad

Anti-Diabetic Combination Tablet Supplier in Bangalore

Dual Therapy Diabetes Tablet Distributor in Hyderabad

Oral Anti-Diabetic Tablet Franchise Opportunity in Jaipur

Type-2 Diabetes Medicine Stockist in Mumbai
Anti-Diabetic Tablet Export & Manufacturing in Chandigarh

Home/Products /glibenclamide-5mg-metformin-500mg-tablet

Glibclay M 500 Tablet

Composition : Glibenclamide (5mg) + Metformin (500mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Glibclay M 500 Tablet combines Glibenclamide 5mg and Metformin 500mg, providing a balanced dual-action approach for managing type-2 diabetes mellitus. It is prescribed for patients who require combination therapy to achieve optimal glycemic control.

Glibenclamide stimulates pancreatic insulin secretion, while Metformin enhances insulin sensitivity and reduces hepatic glucose output. Together, they offer effective control over fasting and postprandial blood sugar levels.

This combination is ideal for patients who do not achieve target glucose levels with monotherapy and ensures long-term metabolic stability. Its oral administration and favorable tolerability profile support adherence and consistent therapy outcomes.

Adding Glibclay M 500 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings in chronic care management, unlocking opportunities in hospital supply, retail pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its high prescription rate ensures continuous demand and strong commercial performance.

Read More

About the Product

Glibclay M 500 Tablet combines Glibenclamide 5mg and Metformin 500mg, providing a balanced dual-action approach for managing type-2 diabetes mellitus. It is prescribed for patients who require combination therapy to achieve optimal glycemic control.

Glibenclamide stimulates pancreatic insulin secretion, while Metformin enhances insulin sensitivity and reduces hepatic glucose output. Together, they offer effective control over fasting and postprandial blood sugar levels.

This combination is ideal for patients who do not achieve target glucose levels with monotherapy and ensures long-term metabolic stability. Its oral administration and favorable tolerability profile support adherence and consistent therapy outcomes.

Adding Glibclay M 500 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings in chronic care management, unlocking opportunities in hospital supply, retail pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its high prescription rate ensures continuous demand and strong commercial performance.

Some patients may experience nausea, vomiting, abdominal discomfort, diarrhea, dizziness, or headache. Hypoglycemia may occur due to Glibenclamide. Rarely, lactic acidosis or allergic reactions may occur.

Glibclay M 500 Tablet is indicated for the management of type 2 diabetes mellitus in patients who require dual therapy for effective glycemic control when diet and exercise alone are insufficient.

Use strictly under medical supervision. Monitor blood glucose regularly to avoid hypoglycemia. Avoid use in patients with severe renal or hepatic impairment. Follow the prescribed dosage and lifestyle recommendations carefully.

Store in a cool, dry place below 25°C, away from light and moisture. Keep out of reach of children.

Get in Touch